Rapid desensitization to acetylsalicylic acid in patients with ischemic heart disease: 10-year experience of a portuguese allergy department
R. Brás
ritasabras@gmail.com1, J. Caiado
1,2, E. Pedro
1Show more: Authors information and Publication history1Department of Immunoallergology, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
2University Clinic of Immunoallergology, Faculty of Medicine, Universidade de Lisboa, Lisbon, Portugal
HistoryPublished: 26 July 2021
Accepted: 26 July 2021
Received: 05 April 2021
Doi10.23822/EurAnnACI.1764-1489.230SummaryIntroduction. Managing Acetylsalicylic Acid (ASA) hypersensitivity (HS) in patients with ischemic heart disease (IHD) is a challenge. Data on Rapid Desensitization (RD) to ASA is scarce. We aimed to report the outcomes of our 10-year experience with RD to ASA.
Methods. Retrospective, observational, single-center study of patients with ASA HS and suspected IHD who underwent RD to ASA between March 2009 and February 2019.
Results. Fifty patients were included. ASA HS presentation ranged from urticaria (56%) to anaphylaxis (32%). Regarding cardiologic diagnoses, 40 patients (80%) had acute coronary syndrome and 10 (20%) stable angina. The majority of patients (N = 36.72%) underwent percutaneous coronary intervention. RD to ASA was successful in all patients. Two patients presented a mild HS reaction during the RD, which was promptly treated, and subsequent daily doses of ASA 100 mg were tolerated.
Conclusions. In our cohort, RD to ASA in patients with ASA HS and IHD was very effective and safe.
Key wordsAcetylsalicylic acid; hypersensitivity; rapid drug desensitization; ischemic heart disease; percutaneous coronary intervention.
FULL TEXT